My watch list  

7 Current news about the topic pioglitazone


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
New strategy may drop cancer's guard


A drug used now to treat Type 2 diabetes may someday help beat breast and ovarian cancers, but not until researchers decode the complex interactions that in some cases help promote tumors, according to Rice University scientists. Rice bioscientist Daniel Carson and alumna Micaela Morgado ...


Diabetes medication reduces dementia risk

Analysis of health insurance data suggests preventive effect


Treating people with type 2 diabetes, also known as "age-related diabetes" with antidiabetics reduces their risk for Alzheimer’s and other types of dementia. The risk is most significantly reduced by the drug pioglitazone. Researchers of the German Center for Neurodegenerative Diseases (DZNE) ...


Approval of Additional Indication of NESINA: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan


Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV (DPP-4) ...


Roche's weekly taspoglutide meets primary end-point in key Phase III study

Taspoglutide demonstrates superiority in HbA1c change versus placebo as add-on to metformin and pioglitazone


Roche announced that its Phase III study T-emerge 3 met its primary endpoint of change in HbA1c. T-emerge 3 is a study of once weekly taspoglutide versus placebo, as add-on to metformin and pioglitazone. The results of T-emerge 3 showed that taspoglutide demonstrated superiority in HbA1c change ...


Obesity and type 2 diabetes market closely linked but vastly different in outlook


The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. This rapid market expansion presents significant opportunities for pharmaceutical companies who are able to develop new therapies to address the unmet clinical ...


Takeda Reacquires Rights to Diabetes Drug in Canada


Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999. "Reacquiring ...


Takeda Wing to Open at the Oxford Centre for Diabetes


Takeda Chemical Industries, Ltd. announced that a new research facility at the Oxford Centre for Diabetes, Endocrinology and Metabolism ("OCDEM", Oxford, UK) was opened and named the "Takeda Wing". This has been under construction with Takeda's donation based on the five year partnership starting ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE